Nanjing Medlander Medical Technology: Investor Relations Activity Schedule (May 7, 2024)
Nanjing Securities Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Nanjing Mailland Medical Technology Co., Ltd.
“Constitution of Nanjing Maillander Medical Technology Co., Ltd.”
Nanjing Securities Co., Ltd. inspection opinions on Nanjing Mailland Medical Technology Co., Ltd.'s use of temporarily idle funds to purchase wealth management products
Notice on applying for comprehensive credit lines from financial institutions in 2024
Announcement of Resolutions of the Fifth Meeting of the Second Board of Directors
2023 Audit Report
Special audit report on the summary table of non-operating capital occupation and other related capital transactions of Nanjing Mailander Medical Technology Co., Ltd.
2023 Independent Director Debriefing Report (Yuan Tianrong)
2023 Internal Control Audit Report
Nanjing Securities Co., Ltd.'s inspection opinion on Nanjing Mailland Medical Technology Co., Ltd.'s use of part of the overraised capital to permanently supplement working capital
Announcement of Resolutions of the Fourth Meeting of the Second Board of Supervisors
Accounting firm performance evaluation report
2023 Independent Director Debriefing Report (Leng Derong)
2023 Independent Director's Debriefing Report (Shu Baixian)
2023 Independent Director Debriefing Report (Hu Jianjun)
Nanjing Mailander Medical Technology Co., Ltd. 2023 Fund Raised Deposit and Use Verification Report
Special report on the storage and actual use of funds raised in 2023
Nanjing Securities Co., Ltd.'s special inspection opinion on the storage and actual use of funds raised by Nanjing Mailand Medical Technology Co., Ltd. in 2023
Announcement on the estimated amount of daily related transactions of the company in 2024
No Data